Therapeutic plasma exchange in renal diseases

Journal of the American Society of Nephrology

Volumn 7, Issue 3, 1996, Pages 367-386

  Madore, François ^a   Lazarus, J Michael ^a   Brady, Hugh R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Harvard Ctr Stud of Kidney Dis   (United States)

Author keywords

Glomerulonephritis; HUS TTP; Multiple myeloma; Plasmapheresis; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DIPYRIDAMOLE; HEPARIN CALCIUM; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GLOMERULONEPHRITIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULITIS;

EID: 0029870937     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v73367     Document Type: Review

References (133)

1. Shumak KH, Rock GA: Therapeutic plasma exchange. N Engl J Med 1984;310:762-71.
2. Pineda AV: Applications of therapeutic apheresis. Mayo Clin Proc 1994;69:893-894.
3. American Medical Association: Panel on Therapeutic Plasmapheresis: Current status of therapeutic plasmapheresis and related techniques. JAMA 1985;253:819-825.
4. Klein H, Balow J, Dau P, et al.: Clinical applications of therapeutic apheresis. J Clin Apheresis 1986;3:1-92.
5. Leitman S, Kucera E, McLeod B, et al. Guidelines for Therapeutic Hemapheresis. Bethesda, MD: American Association of Blood Banks: 1992.
6. Strauss RG, Ciavarella D, Gilcher RO, et al.: An overview of current management. J Clin Apheresis 1993;8: 195-210.
7. Wahlin A, Lofvenberg E, Holm J: Improved survival in multiple myeloma with renal failure. Acta Med Scand 1987;221:205-209.
8. Kelton JG, Neame PB, Walker I, et al.: Thrombotic thrombocytopenic purpura: Mechanism for effectiveness of plasmapheresis [Abstract]. Clin Res 1979;27: 299A.
9. Dantal J, Bigot E, Bogers W, et al.: Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994;330:7-14.
10. Byrnes JJ, Khurana M: Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977;297:1386-1389.
11. Lockwood CM, Worlledge S, Nicholas A, Cotton C, Peters DK: Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med 1979;300:524-530.
12. Low A, Hotze A, Krapf F, et al.: The nonspecific clearance function of the reticuloendothelial system in patients with immune complex mediated diseases before and after therapeutic plasmapheresis. Rheumatol Int 1985;5:69-72.
13. Bystryn JC, Graf MW, Uhr JW: Regulation of antibody formation by serum antibody. Removal of specific antibody by means of exchange transfusion. J Exp Med 1970;132:1279-1287.
14. Euler HH, Schroeder JO, Zeuner RA, Teske E: A randomized trial of plasmapheresis and subsequent pulse cyclophosphamide in severe lupus: Design of the LPSG trial. Int J Artif Organs 1991;14:639-646.
15. Hakim RH, Siami A. Plasmapheresis. In: Daugirdas JT, Ing T, Eds. Handbook of Dialysis. 2nd Ed. Boston: Little, Brown; 1994:219-241.
16. Samtleben W, Gurland H. Plasma exchange: Principles and practice. In: Maher JF, Ed. Replacement of Renal Function by Dialysis. 3rd ed. Dordrecht: Kluwer Academic Publishers; 1989:460-474.
17. Hakim RM, Schulman G, Churchill WJ, Lazarus JM: Successful management of thrombocytopenia, microangiopathic anemia, and acute renal failure by plasmapheresis. Am J Kidney Dis 1985;5:170-176.
18. Tisher CC, Brenner BM. Renal pathology with clinical and functional correlations. Philadelphia: J.B. Lippincott; 1989.
19. Wilson CD, Dixon FJ: Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 1973;3:74-89.
20. Rees AJ. Goodpasture's syndrome. In: Glassock RJ, Ed. Current Therapy in Nephrology and Hypertension. St. Louis: Mosby-Year Book; 1992:173-178.
21. Johnson JP, Moore JJ, Austin HB, Balow JE, Antonovych TT, Wilson CB: Therapy of anti-glomerular basement membrane antibody disease: Analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 1985;64:219-227.
22. Simpson IJ, Doak PB, Williams LC, et al.: Plasma exchange in Goodpasture's syndrome. Am J Nephrol 1982;2:301-311.
23. Couser WG: Rapidly progressive glomerulonephritis: Classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis 1988;11:449-464.
24. Lockwood CM, Boulton JJ, Lowenthal RM, Simpson IJ, Peters DK: Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis. Br Med J 1975;2:252-254.
25. Lockwood CM, Rees AJ, Pearson TA, Evans DJ, Peters DK, Wilson CB: Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome. Lancet 1976;1:711-715.
26. Pusey CD, Lockwood CM: Plasma exchange and immunosuppressive drugs in the management of severe glomerulonephritis. Prog Clin Biol Res 1982;106:91-104.
27. Peters DK, Rees AJ, Lockwood CM, Pusey CD: Treatment and prognosis in antibasement membrane antibody-mediated nephritis. Transplant Proc 1982;14: 513-521.
28. Pusey CD, Lockwood CM, Peters DK: Plasma exchange and immunosuppressive drugs in the treatment of glomerulonephritis due to antibodies to the glomerular basement membrane. Int J Artif Organs 1983;1:15-18.
29. Pusey CD, Lockwood CM: Antibody mediated glomerulonephritis: Clinical and experimental studies. J Clin Apheresis 1985;2:396-404.
30. Ewert BH, Jennette JC, Falk RJ: Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992;41:375-383.
31. Falk RJ, Terrell R, Charles LA, et al.: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990;87:4114-4119.
32. Kain R, Matsui K, Exner M, et al.: A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: The lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med 1995;181:585-597.
33. Glöckner WM, Sieberth HG, Wichmann HE, et al.: Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: A controlled, multicenter study. Clin Nephrol 1988;29:1-8.
34. Cole E, Cattran D, Magil A, et al.: A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis 1992;20:261-269.
35. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM: Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40:757-763.
36. Rifle G, Dechelette E: Treatment of rapidly progressive glomerulonephritis by plasma exchange and methylprednisolone pulses. A prospective randomized trial of cyclophosphamide. Interim analysis. The French Cooperative Group. Prog Clin Biol Res 1990;337:263-267.
37. Mauri JM, Gonzales MT, Poveda R, et al.: Therapeutic plasma exchange in the treatment of rapidly progressive glomerulonephritis. Plasma Ther & Transfus Technol 1985;6:587-591.
38. Clough JD, Calabrese LH: Theoretical aspects of immune complex removal by plasmapheresis. Plasma Ther Transfus Technol 1981;2:73-81.
39. Derksen RH, Schuurman HJ, Gmelig Meyling FHJ, Verroust P, Kater L: Circulating immune complexes in systemic lupus erythmatosus: Relation to disease activity and the effect of plasma exchange. Plasma Ther & Transfus Technol 1985;6:327-335.
40. Jones JV, Robinson MF, Parciany RK, Layfer LF, McLeod B: Therapeutic plasmapheresis in systemic lupus erythematosus. Effects on immune complexes and antibodies to DNA. Arthritis Rheum 1981;24:1113-1120.
41. Jones JV, Cumming RH, Bucknall RC, Asplin CM: Plasmapheresis in the management of acute lupus erythematosus. Lancet 1976;1:709-711.
42. Jones JV, Cumming RH, Bacon PA, et al.: Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus. Q J Med 1979;48:555-576.
43. Leaker BR, Becker GJ, Dowling JP, Kincaid-Smith P: Rapid improvement in severe lupus glomerular lesions following intensive plasma exchange associated with immunosuppression. Clin Nephrol 1986;25:236-244.
44. Moriconi L, Ferri C, Fanara G, et al.: Plasma exchange in the treatment of lupus nephritis. Int J Artif Organs 1983;1:35-38.
45. Vangelista A, Frasca G, Orsi C, Sermasi G, Zucchelli P, Bonomini V: Short-term plasmapheresis in acute lupus nephritis. Int J Artif Organs 1983;1:43-46.
46. Lewis EJ, Hunsicker LG, Lan SP, Ronde RD, Lachin JM: A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992;326:1373-1379.
47. Wei N, Klippel JH, Huston DP, et al.: Randomized trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1983;1:17-22.
48. Derksen RH, Hene RJ, Kallenberg CG, Valentijn RM, Kater L: Prospective multicentre trial on the short-term effects of plasma exchange versus cytotoxic drugs in steroid-resistant lupus nephritis. Neth J Med 1988;33: 168-177.
49. The French Cooperative Group. A randomized trial of plasma exchange in severe acute systemic lupus erythematosous: Methodology and interim analysis. Plasma Ther & Transfus Technol 1985;6:535-539.
50. Clark WF, Cattran DC, Balfe JW, Williams W, Lindsay RM, Linton AL: Chronic plasma exchange in systemic lupus erythematosus nephritis. Proc Eur Dial Transplant Assoc 1983;20:629-635.
51. Bystryn JC, Schenkhein I, Uhr JW. A model for regulation of antibody synthesis by serum antibody. In: Amos B, Ed. Progress in Immunology. New York: Academic Press; 1971:627-636.
52. Euler HH, Schroeder JO: Plasmapheresis for lupus nephritis. Lupus Plasmapheresis Study Group. N Engl J Med 1992;327:1029-1030.
53. Schroeder JO, Euler HH, Löffler H: Synchronization of plasmapheresis and pulse cyclophosphamide in systemic lupus erythematosus. Ann Int Med 1987;107: 344-346.
54. Barr WG, Hubbel EA, Robinson JA: Plasmapheresis and pulse cyclophosphamide in systemic lupus erythematosus. Ann Int Med 1988;108:152-153.
55. Huston DP, Bressler RB, Suki WN, et al.: A controlled study of pulse cyclophosphamide and plasmapheresis therapy of lupus nephritis [Abstract]. Arthritis Rheum 1988;31[Suppl 55]:31A.
56. Zielinski C, Mueller C, Smolen J: Plasmapheresis in the treatment of systemic lupus erythematosus: A controlled study. Acta Med Austriaca 1988;15:155-158.
57. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M: Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775-788.
58. D'Amico G, Fornasieri A: Cryoglobulinemic glomerulonephritis: A membranoproliferative glomerulonephritis induced by hepatitis C virus. Am J Kidney Dis 1994;25: 361-369.
59. Frankel AH, Singer DR, Winearls CG, Evans DJ, Rees AJ, Pusey CD: Type II essential mixed cryoglobulinaemia: Presentation, treatment and outcome in 13 patients. Q J Med 1992;82:101-124.
60. Gorevic PD, Kassab HJ, Levo Y, et al.: Mixed cryoglobulinemia: Clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69:287-308.
61. Geltner D, Kohn RW, Gorevic P, Franklin EC: The effect of combination therapy (steroids, immunosuppressives, and plasmapheresis) on 5 mixed cryoglobulinemia patients with renal, neurologic, and vascular involvement. Arthritis Rheum 1981;24:1121-1127.
62. Berkman EM, Orlin JB: Use of plasmapheresis and partial plasma exchange in the management of patients with cryoglobulinemia. Transfusion 1980;20:171-178.
63. Ferri C, Moriconi L, Gremignai G, et al.: Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange. Nephron 1986;43:246-253.
64. Singer DR, Venning MC, Lockwood CM, Pusey CD: Cryoglobulinaemia: Clinical features and response to treatment. Ann Med Interne 1986;137:251-253.
65. Sinico RA, Fornasieri A, Fiorini G, et al.: Plasma exchange in the treatment of essential mixed cryoglobulinemia nephropathy. Long-term follow up. Int J Artif Organs 1985;2:15-18.
66. Valbonesi M, Montani F, Mosconi L, Florio G, Vecchi C: Plasmapheresis and cytotoxic drugs for mixed cryoglobulinemia. Haematologia (Budap) 1984;17:341-351.
67. L'Abbate A, Maggiore Q, Caccamo A, et al.: Long term effects of cryoapheresis and cytostatic treatment in essential mixed cryoglobulinemia. Int J Artif Organs 1985;2:19-22.
68. Schena FP, Manno C, Dimonte D, et al.: Plasma-exchange in the treatment of cryoglobulinemia. Ric Clin Lab 1983;13:133-140.
69. Galla JH: IgA nephropathy. Kidney Int 1995;47:377-387.
70. Glassock RJ: Natural history and treatment of primary proliferative glomerulonephritis: A review. Kidney Int Suppl 1985;[Suppl 17]:S136-S142.
71. Lopez-Trascasa M, Egido J, Sancho J, Hernando L: IgA glomerulonephritis (Berger's disease): Evidence of high serum levels of polymeric IgA. Clin Exp Immunol 1980; 42:247-254.
72. Coppo R, Basolo B, Roccatello D, Piccoli G: Plasma exchange in primary IgA nephropathy and Henoch-Schönlein. Plasma Ther & Transfus Technol 1985;6: 705-723.
73. Chalopin JM, Tanter Y, Rifle G: Plasma exchange and IgA nephropathies [Abstract]. Eur J Clin Invest 1983; 13:45A.
74. Coppo R, Basolo B, Roccatello D, et al.: Plasma exchange in progressive primary IgA nephropathy. Int J Artif Organs 1985;2:55-58.
75. Coppo R, Basolo B, Giachino O, et al.: Plasmapheresis in a patient with rapidly progressive idiopathic IgA nephropathy: removal of IgA-containing circulating immune complexes and clinical recovery. Nephron 1985; 40:488-490.
76. Hene RJ, Kater L: Plasmapheresis in nephritis associated with Henoch-Schonlein purpura and in primary IgA nephropathy. Plasma Ther & Transfus Technol 1983;4:165-173.
77. Kauffmann RH, Houwert DA: Plasmapheresis in rapidly progressive Henoch-Schoenlein glomerulonephritis and the effect on circulating IgA immune complexes. Clin Nephrol 1981;16:155-160.
78. Lai KN, Lai FM, Leung AC, Ho CP, Vallance OJ: Plasma exchange in patients with rapidly progressive idiopathic IgA nephropathy: A report of two cases and review of literature. Am J Kidney Dis 1987;10:66-70.
79. Nicholls K, Becker G, Walker R, Wright C, Kincaid-Smith P: Plasma exchange in progressive IgA nephropathy. J Clin Apheresis 1990;5:128-132.
80. Byrnes JJ, Moake JL: Thrombotic thrombocytopenic purpura and the haemolytic-uraemia syndrome: evolving concept of pathogenesis and therapy. Clin Haematol 1986;15:413-442.
81. Remuzzi G: HUS and TTP: Variable expression of a single entity. Kidney Int 1987;32:292-308.
82. Shepard KV, Bukowski RM: The treatment of thrombotic thrombocytopenic purpura with exchange transfusions, plasma infusions, and plasma exchange. Semin Hematol 1987;24:178-193.
83. Amorosi EL, Ultmann JE: Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature. Medicine (Baltimore) 1966;45:139-159.
84. Bukowski RM, Hewlett JS, Reimer RR, Groppe CW, Weick JK, Livingston RB: Therapy of thrombotic thrombocytopenic purpura: An overview. Semin Thromb Hemostasis 1981;7:1-8.
85. Ridolfi RL, Bell WR: Thrombotic thrombocytopenic purpura: Report of 25 cases and review of the literature. Medicine (Baltimore) 1981;60:413-428.
86. Pisciotto P, Rosen D, Silver H, et al.: Treatment of thrombotic thrombocytopenic purpura. Evaluation of plasma exchange and review of the literature. Vox Sang 1983;45:185-196.
87. Onundarson PT, Rowe JM, Heal JM, Francis CW: Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution. Arch Intern Med 1992;152:791-796.
88. French Cooperative Study Group for Adult HUS: Adult hemolytic uremic syndrome with renal microangiopathy. Outcome according to therapeutic protocol in 53 cases. Ann Med Interne 1992;143[Suppl 1]:27-32.
89. Iacone A, Dragani A, Di GG, et al.: Thrombotic thrombocytopenic purpura (TTP) treatment: Italian cooperative retrospective study on 29 cases. Haematologica 1986;71:39-43.
90. Gianviti A, Perna A, Caringella A, et al.: Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome. Am J Kidney Dis 1993;22:264-266.
91. Rock GA, Shumak KH, Buskard NA, et al.: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325: 393-397.
92. Henon P: Treatment of thrombotic thrombopenic purpura. Results of a multicenter randomized clinical study. Presse Med 1991;20:1761-1767.
93. Byrnes JJ, Moake JL, Klug P, Periman P: Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 1990;34:169-174.
94. Dayoan EJ, Dixon AC, Rizzo E, Nakamura JM: Refractory thrombotic thrombocytopenic purpura: Successful treatment by plasmapheresis with plasma cryosupernatant. Haematologica 1993;78:389-392.
95. Obrador GT, Zeigler ZR, Shadduck RK, Rosenfeld CS, Hanrahan JB: Effectiveness of the cryosupernatant therapy in refractory and chronic relapsing thrombotic thrombocytopenic purpura. Am J Hematol 1993;42: 217-220.
96. DeFronzo RA, Cooke CR, Wright JR, Humphrey RL: Renal function in patients with multiple myeloma. Medicine (Baltimore) 1978;57:151-166.
97. Fang LST: Light chain nephropathy. Kidney Int 1985; 27:582-592.
98. Misiani R, Tiraboschi G, Mingardi G, Mecca G: Management of myeloma kidney: An anti-light-chain approach. Am J Kidney Dis 1987;10:28-33.
99. Pozzi C, Pasquali S, Donini U, et al.: Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: A review of 50 cases. Report of the Italien Renal Immunopathology Group. Clin Nephrol 1987;28:1-9.
100. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE: Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990;150:863-869.
101. Zucchelli P, Pasquali S, Cagnoli L, Rovinetti C: Plasma exchange therapy in acute renal failure due to light chain myeloma. Trans Am Soc Artif Intern Organs 1984;30:36-39.
102. Keown PA: The highly sensitized patient: Etiology, impact and management. Transplant Proc 1987;19: 74-78.
103. Frasca GM, Martella D, Vangelista A, Bonomini V: Ten years experience with plasma exchange in renal transplantation. Int J Artif Organs 1991;14:51-55.
104. Hakim RM, Milford E, Himmelfarb J, Wingard R, Lazarus JM, Watt RM: Extracorporeal removal of anti-HLA antibodies in transplant candidates. Am J Kidney Dis 1990;16:423-431.
105. Palmer A, Taube D, Welsh K, Bewick M, Gjorstrup P, Thick M: Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989;1:10-12.
106. Taube DH, Williams DG, Cameron JS, et al.: Renal transplantation after removal and prevention of resynthesis of HLA antibodies. Lancet 1984;1:824-828.
107. Taube D, Palmer A, Welsh K, Bewick M, Snowden S, Thick M: Removal of anti-HLA antibodies prior to transplantation: An effective and successful strategy for highly sensitized renal allograft recipients. Transplant Proc 1989;694-695.
108. Reisaeter AV, Fauchald P, Leivestad T, et al.: Plasma exchange in highly sensitized patients as induction therapy after renal transplantation. Transplant Proc 1994;26:1758.
109. Blake P, Sutton D, Cardella CJ: Plasma exchange in acute renal transplant rejection. Prog Clin Biol Res 1990;337:249-252.
110. Allen NH, Dyer P, Geoghegan T, Harris K, Lee HA, Slapak M: Plasma exchange in acute renal allograft rejection. A controlled trial. Transplantation 1983;35: 425-428.
111. Kirubakaran MG, Disney AP, Norman J, Pugsley DJ, Mathew TH: A controlled trial of plasmapheresis in the treatment of renal allograft rejection. Transplantation 1981;32:164-165.
112. Bonomini V, Vangelista A, Frasca GM, Di FA, Liviano DG: Effects of plasmapheresis in renal transplant rejection. A controlled study. Trans Am Soc Artif Intern Organs 1985;31:698-703.
113. Cardella CJ, Sutton DM, Katz A, et al. In: Zurukzoglu W, Papadimitriou M, Pyrpasopoulos M, Eds. Eighth International Congress of Nephrology. Athens, Greece: Karger; 1981:681.
114. Cardella CJ, Sutton DM, Katz A, et al.: A controlled trial evaluating intensive plasma exchange in renal transplant recipients. Proc Eur Dial Transplant Assoc 1980;17:429-434.
115. Hendrick A, Wallin JD, O'Neill WJ: Plasma exchange in chronic renal allograft rejection. Transplantation 1984; 37:318-319.
116. Rifle G, Chalopin JM, Turc JM, et al.: Plasmapheresis in the treatment of renal allograft rejections. Transplant Proc 1979;11:20-26.
117. Li PK, Lai FM, Leung CB, Lui SF, Wang A, Lai KN: Plasma exchange in the treatment of early recurrent focal glomerulosclerosis after renal transplantation. Report and review. Am J Nephrol 1993;13:289-292.
118. Mowry J, Marik J, Cohen A, Hogg R, Sahney S, Ettenger R: Treatment of recurrent focal segmental glomerulosclerosis with high-dose cyclosporine A and plasmapheresis. Transplant Proc 1993;25:1345-1346.
119. Mokrzycki MH, Kaplan AA: Therapeutic plasma exchange: Complications and management. Am J Kidney Dis 1994;23:817-827.
120. Borberg H. Problems of plasma exchange therapy. In: Gurland HJ, Heinze V, Lee HA, Eds. Therapeutic Plasma Exchange. New York: Springer-Verlag; 191; 1980:201.
121. Aufeuvre J, Morin-Hertel F, Cohen-Solal M, Lefloch A, Baudelot J. Hazards of plasma exchange. In: Sieberth H, Ed. Plasma Exchange. Stuttgart, Germany: FK Schattauer Verlag; 1980:149-157.
122. Ziselman E, Bongiovanni M, Wurzel H: The complications of therapeutic plasma exchange. Vox Sang 1984; 46:270-276.
123. Fabre M, Andreu G, Mannoni P. Some biological modifications and clinical hazards observed during plasma exchanges. In: Seiberth H, Ed. Plasma Exchange. Stuttgart, Germany: FK Schattauer Verlag; 1980:143-148.
124. Rossi P, Cecchini L, Minichella G, et al.: Comparison of the side effects of therapeutic cytapheresis and those of other types of hemapheresis. Haematologia 1991;76: 75-80.
125. Sprenger K, Rasche H, Franz H: Membrane plasma separation: Complications and monitoring. Artif Organs 1984;8:360-363.
126. Samtleben W, Hillebrand G, Krumme D, Gurland H. Membrane plasma separation: Clinical experience with more than 120 plasma exchanges. In: Seiberth H, Ed. Plasma Exchange. Stuttgart, Germany: FK Schattauer Verlag; 1980:23-27.
127. Sutton D, Nair R, Rock G: The Canadian Apheresis Study Group: Complications of plasma exchange. Transfusion 1989;29:124-127.
128. Owen HG, Brecher ME: Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion 1994;34:891-894.
129. Hind CR, Paraskevakou H, Lockwood CM, Evans DJ, Peters DK, Rees AJ: Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA 1980;244:2423-2426.
130. Lockwood CM, Worlledge S, Nicholas A, Cotton C, Peters DK: Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis. Lancet 1977;1:63-67.
131. Walker RG, d'Apice AJ, Becker GJ, Kincaid-Smith P, Craswell PW: Plasmapheresis in Goodpasture's syndrome with renal failure. Med J Aust 1977;1:875-879.
132. Wing EJ, Bruns FJ, Fraley DS, Segel DP, Adler S: Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA 1980;244: 2423-2426.
133. Pohl MA, Lan SP, Berl T: Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann Intern Med 1991;114:924-929.